dr. mok on the utility of afatinib in lung cancer
Published 11 years ago • 1K plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
0:59
dr. mok gives an overview of plasma testing approaches for lung cancer
-
0:44
dr. mok on dacomitinib for first-line lung cancer treatment
-
1:38
dr. mok on improving lung cancer drug development
-
2:57
dr mok on the efficacy of taletrectinib in ros1 nsclc
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
1:02
dr. mok on overall survival data from the alex trial in alk lung cancer
-
0:49
dr. mok on plasma testing in lung cancer
-
0:58
the activity of afatinib in lung cancer
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
4:06
afatinib in patients with uncommon egfr mutations
-
2:34
afatinib: dose modifications and adverse events
-
1:34
dr. fidler on the utility of dacomitinib in egfr-mutant nsclc
-
3:08
side effect management with afatinib
-
2:10
afatinib versus erlotinib in patients with advanced scc
-
1:35
dr. bunn discusses afatinib for patients with egfr mutation
-
1:30
dr. langer on afatinib for advanced non-small cell lung cancer
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer